Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.California-based Selva Therapeutics has closed a Series A round with $3m raised.
The funding for the round came from private investors, including Board of Directors member Kenneth Kelley; other participants of the round were not disclosed.
The proceeds of the Series A will be used to advance Selva’s lead candidate, SLV213, into clinical trials for Covid-19. The company’s CEO Ted Daley explains that it is currently completing pre-clinical studies of SLV213, but this funding will allow Selva to “open an IND [investigational new drug] application, and start manufacturing of the clinical drug supply” before processing into a Phase.